With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.80636-30-2,3,3-Dimethyl-3,4-dihydroquinoxalin-2(1H)-one,as a common compound, the synthetic route is as follows.
80636-30-2, A solution of the compound obtained in the above step (1) (300 mg) in concentrated sulfuric acid (12 mL) was cooled to -15 C, and thereto was added dropwise a solution of nitric acid (44 muL) in concentrated sulfuric acid (0.6 mL). The mixture was stirred at the same temperature for 3 hours. To the reaction mixture was added sodium hydroxide (5.4 g) and ice, and the mixture was extracted with ethyl acetate. The organic layer was washed successively with water and brine, dried over sodium sulfate and concentrated in vacuo. The resultant residue was suspended in ethyl acetate- diethylether, and the precipitates were collected by filtration. The resultant solid was purified by column chromatography on NH-silica gel (Chromatorex NH-silica gel, solvent; n-hexane/ethyl acetate = 4/1 ? 1/4) to give 3,3-dimethyl-6-nitro-3,4- dihydro- quinoxalin-2(lH)-one (26 mg) as a yellow powder. MS(APCI) m/z: 222 [M+H]+
As the paragraph descriping shows that 80636-30-2 is playing an increasingly important role.
Reference£º
Patent; TANABE SEIYAKU CO., LTD.; WO2007/89034; (2007); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider